ChemioCare Inc., a pharmaceutical company working on a proprietary transdermal delivery platform, has closed a private round of financing, raising $[mepr-active rule=”374″ ifallowed=”hide”]★Research Note – Subscriber ONLY content: read our research and get insight on this and other deals. We offer monthly or yearly recurring or one-time trial subscriptions. Subscribe today and see what you have been missing! ★[/mepr-active][mepr-active rule=”374″]2,474,765 from 61 investors from BC, Alberta, Ontario, Belgium, Germany, Switzerland, Thailand, UK and USA. The company issued common shares priced at US $0.07 to US $0.55. Large portion of the funding came from 41 BC investors ($1.37 million) and 9 US investors ($0.64 million) . Canaccord Genuity Corp. acted as placement agent and Norton Rose Fulbright Canada LLP acted as legal counsel.[/mepr-active]
ChemioCare’s Vision is to transform current treatment of chemotherapy-induced nausea and vomiting through patch technology.
New York City and Vancouver based based ChemioCare is a newly formed BC company.
photo credit: ChemioCare